University of Minnesota. Driven to Discover.
Funds will help combat resistance, launch a TB surveillance center.
The results suggest that clinical labs should consider using an additional test to validate results.
Two companies that have received funds—Spero Therapeutics and Entasis Therapeutics—say CARB-X support has been instrumental.
"If we can eradicate the empirical use of antibiotics . . . we can achieve a lot," Zowawi says.
The alliance aims to aid collaboration between the public and private sectors.
A national lab network can identify emerging threats and track resistance trends.
Though results are mixed, point-of-care testing could reduce antibiotic use.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.